X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fulford India with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TEVA PHARMA (Israel) - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FULFORD INDIA   TEVA PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TEVA PHARMA
Dec-13
FULFORD INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs9422,677-   
Low Rs4502,326-   
Sales per share (Unadj.) Rs691.41,536.5-  
Earnings per share (Unadj.) Rs11.596.0-  
Cash flow per share (Unadj.) Rs15.4220.2-  
Dividends per share (Unadj.) Rs2.0084.02-  
Dividend yield (eoy) %0.33.4 8.6%  
Book value per share (Unadj.) Rs380.01,706.7-  
Shares outstanding (eoy) m3.90848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.6 61.8%   
Avg P/E ratio x60.726.1 233.0%  
P/CF ratio (eoy) x45.311.4 398.9%  
Price / Book Value ratio x1.81.5 125.0%  
Dividend payout %17.487.5 19.9%   
Avg Mkt Cap Rs m2,7142,121,238 0.1%   
No. of employees `0000.444.9 1.0%   
Total wages/salary Rs m5050-   
Avg. sales/employee Rs Th6,073.028,989.7 20.9%   
Avg. wages/employee Rs Th1,137.40-   
Avg. net profit/employee Rs Th100.71,811.0 5.6%   
INCOME DATA
Net Sales Rs m2,6961,302,940 0.2%  
Other income Rs m1250-   
Total revenues Rs m2,8221,302,940 0.2%   
Gross profit Rs m-46356,811 -0.0%  
Depreciation Rs m15105,318 0.0%   
Interest Rs m1025,592 0.0%   
Profit before tax Rs m54225,901 0.0%   
Minority Interest Rs m01,026 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-148,292 0.0%   
Tax Rs m10-2,758 -0.3%   
Profit after tax Rs m4581,394 0.1%  
Gross profit margin %-1.727.4 -6.3%  
Effective tax rate %17.7-1.2 -1,448.1%   
Net profit margin %1.76.2 26.5%  
BALANCE SHEET DATA
Current assets Rs m1,738880,001 0.2%   
Current liabilities Rs m545767,435 0.1%   
Net working cap to sales %44.38.6 512.4%  
Current ratio x3.21.1 278.3%  
Inventory Days Days4891 53.4%  
Debtors Days Days496 4.5%  
Net fixed assets Rs m12425,569 0.0%   
Share capital Rs m393,207 1.2%   
"Free" reserves Rs m1,4430-   
Net worth Rs m1,4821,447,319 0.1%   
Long term debt Rs m0666,222 0.0%   
Total assets Rs m2,0772,977,635 0.1%  
Interest coverage x6.79.8 68.3%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.4 296.7%   
Return on assets %2.63.6 72.6%  
Return on equity %3.05.6 53.6%  
Return on capital %4.34.9 87.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Net fx Rs m-6560-   
CASH FLOW
From Operations Rs m90207,621 0.0%  
From Investments Rs m105-73,569 -0.1%  
From Financial Activity Rs m-14-249,056 0.0%  
Net Cashflow Rs m181-115,003 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.14 Rs / USD

Compare FULFORD INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare FULFORD INDIA With: PFIZER  JUBILANT LIFE SCIENCES  ELDER PHARMA  NATCO PHARMA  SUN PHARMA  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS